Brief: Eloxx Pharmaceuticals Announces Initiation Of Phase 2 Clinical Study Evaluating Elx-02 For Treatment Of Alport Syndrome With First Patient Dosed
27/02/2023 22:27
Feb 27 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2
CLINICAL
STUDY EVALUATING ELX-02 FOR TREATMENT OF ALPORT SYNDROME WITH
FIRST PATIENT DOSED
* ELOXX PHARMACEUTICALS INC - TOPLINE RESULTS ARE EXPECTED
IN
FIRST HALF OF 2023
Source text for Eikon: ID:nGNX5tx3GC
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))